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Abstract
Background: The somatic mutation in the FOXL2 gene c.402C.G (p.Cys134Trp) has recently been identified in the vast
majority of adult ovarian granulosa cell tumors (OGCTs) studied. In addition, this mutation seems to be specific to adult
OGCTs and is likely to be a driver of malignant transformation. However, its pathogenic mechanisms remain elusive.
Methodology/Principal Findings: We have sequenced the FOXL2 open reading frame in a panel of tumor cell lines (NCI-60,
colorectal carcinoma cell lines, JEG-3, and KGN cells). We found the FOXL2 c.402C.G mutation in the adult OGCT-derived
KGN cell line. All other cell lines analyzed were negative for the mutation. In order to gain insights into the pathogenic
mechanism of the p.Cys134Trp mutation, the subcellular localization and mobility of the mutant protein were studied and
found to be no different from those of the wild type (WT). Furthermore, its transactivation ability was in most cases similar
to that of the WT protein, including in conditions of oxidative stress. A notable exception was an artificial promoter known
to be coregulated by FOXL2 and Smad3, suggesting a potential modification of their interaction. We generated a 3D
structural model of the p.Cys134Trp variant and our analysis suggests that homodimer formation might also be disturbed
by the mutation.
Conclusions/Significance: Here, we confirm the specificity of the FOXL2 c.402C.G mutation in adult OGCTs and begin the
exploration of its molecular significance. This is the first study demonstrating that the p.Cys134Trp mutant does not have a
strong impact on FOXL2 localization, solubility, and transactivation abilities on a panel of proven target promoters, behaving
neither as a dominant-negative nor as a loss-of-function mutation. Further studies are required to understand the specific
molecular effects of this outstanding FOXL2 mutation.
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Introduction
FOXL2 encodes a protein belonging to the Forkhead/Winged-
Helix family of transcription factors. In 2001, its mutations were
implicated as the cause of the Blepharophimosis Ptosis Epicanthus-
inversus Syndrome (BPES; MIM 110100) in humans [1]. This
genetic disorder is characterized by craniofacial abnormalities,
either isolated (BPES type II) or in association with premature
ovarian failure (BPES type I) [2]. FOXL2 has been detected in the
nuclei of ovarian granulosa cells, pituitary thyrotrope and
gonadotrope cells and in the peri-ocular mesenchyma [3,4,5,6]
but some lines of evidence suggest the existence of a wider
expression pattern [7,8,9]. Numerous germline FOXL2 mutations
have been described in association with BPES, including missense,
nonsense, frameshift mutations and in-frame expansions of the
polyalanine tract [10].
Recently, two clinical studies have linked somatic perturbations
of FOXL2 with the occurrence of Ovarian Granulosa Cell
Tumors (OGCT) [11,12]. OGCTs are a rare form of malignancy
affecting women of all ages, with two distinct clinical presentations
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diagnosed early and their prognosis is generally good, though
recurrences and metastases have been reported [14]. However, in
the adult cases of OGCTs, 20% of patients die of the
consequences of their tumor, with a 5-year survival of advanced
oncological stage patients being less than 50% [13]. These tumors
have a tendency to late recurrence, with latency after primary
tumor treatment of up to 37 years. Moreover, chemotherapy has
limited success and surgery remains the main treatment option.
In an effort to identify a specific marker of adult OGCTs, Shah
and collaborators uncovered a single recurrent somatic FOXL2
mutation (c.402C.G; p.Cys134Trp, hereafter referred to as
C134W) through high-throughput whole-transcriptome sequenc-
ing of four independent OGCT samples. Moreover, they
confirmed it in 86 out of 89 independent OCGT samples [12].
Interestingly, Cys134 is a highly evolutionarily conserved residue
in the FOXL2 protein sequence, which is predicted to lie in the
second Wing structure of its Forkhead/Winged-helix domain.
Interestingly, FOXL2 has been suggested to be a potential
tumor suppressor in colorectal cancer (CRC) [15]. Indeed, the
FOXL2 locus was found to be hypermethylated in CRC cell lines
and primary tumor samples with inhibition of its expression,
whereas the locus was unmethylated in healthy tissue. Moreover,
FOXL2 overexpression inhibited colony formation in the
HCT116 CRC cell line (although the contribution of some degree
of toxicity to this phenomenon remains to be determined). Thus,
FOXL2 might act as a tumor suppressor in a more systematic way
than anticipated. We have reviewed in detail other molecular links
between FOXL2 and tumor suppression according to the known
literature, and proposed that FOXL2 could indeed act as a novel
tumor suppressor [8].
In this study, we determined the sequence of FOXL2 in a panel
of tumor cell lines (NCI-60 panel, 34 established CRC cell lines, as
well as the JEG-3 and KGN cell line). In order to better
understand the pathogenic mechanism of the C134W mutation,
we set out to characterize its molecular behavior. Specifically, we
studied the subcellular localization of the FOXL2-C134W variant,
as well as its mobility. We analyzed its transactivation ability, as
compared to known type I or II BPES associated variants, on
known targets, in two different cell lines. Finally, we also generated
a 3D-structural model of the C134W variant dimer to compare
with the WT one.
Results and Discussion
FOXL2 Genotyping in Established Tumor Cell Lines of
Various Tissue Origins
In order to assess the potential implication of the somatic
mutation c.402C.G in the malignant transformation of various
tissues including the ovary, we sequenced FOXL2 in a large variety
of established and well-characterized cancer cell lines. For this
purpose, we obtained genomic DNA from 51 different cancer cell
lines from the NCI-60 panel. We also sequenced the genomic
DNA from the adult OGCT cell line KGN, to uncover whether it
carried the described recurrent mutation c.402C.G [16], as well
as the choriocarcinoma cell line JEG-3, derived from placental
tissue, in which mRNA FOXL2 expression has been detected
(GEO dataset GSE13475; [17]). Moreover, as the methylation
status of the FOXL2 locus was found to be modified in colorectal
cancers (CRC)[15], we hypothesized that other inactivating
mechanisms, such as somatic mutations in the coding region,
might also be involved in CRC pathogenesis. Therefore, we also
analyzed the FOXL2 genomic DNA sequence from 38 CRC cell
lines [18].
Briefly, the c.402C.G (p.Cys134Trp) somatic mutation was
found at the heterozygous state in the KGN cell line (Figure S1),
but was not detected in any other cell line (Table S1). We also
found several occurrences of the known polymorphisms
[c.501C.T (p.Phe167Phe), dbSNP: rs61750361 and c.536C.G
(p.Ala179Gly), dbSNP: rs7432551] that were systematically found
to occur in cis, whether at the homozygous (hemizygous?) or
heterozygous state (Figure S1). A new silent polymorphism was
also detected in the NCI-H460 Non-Small Cell Lung cancer cell
line as well as in the colorectal cancer cell line HCA7 (c.858T.G,
i.e. p.Pro257Pro; Figure S1). Consistently, while this paper was in
preparation, Schrader and collaborators published the absence of
the c.402C.G mutation in the NCI-60 cell line panel and its
presence at the heterozygous state in KGN cells, underlying its
specificity for OGCTs [19].
The absence of the c.402C.G mutation in other types of
cancer than adult OGCT, such as in CRC, does not necessarily
negate a potential implication of FOXL2 inactivation in the
pathogenesis process. An epigenetic mechanism underlying
FOXL2 inactivation cannot be excluded, as somatic hypermethyla-
tion of the FOXL2 locus was recently demonstrated in CRC [15].
From an epigenetic viewpoint, it is also noteworthy that
inactivation of FOXL2 in juvenile OGCT cases is correlated with
tumor mitotic index and aggressivity, although FOXL2 mutations
are rarely present [11,12].
Apart from epimutations, the occurrence of regulatory variants
within the untranslated regions (UTRs), the core promoter or
long-range regulatory elements should be considered. Indeed,
deletions involving long-range regulatory regions containing
Conserved Non-Genic sequences (CNGs) have recently been
reported at the constitutional level as a cause of BPES [9,20]. In
addition, a constitutional variation in the FOXL2 39UTR was
found to cosegregate with BPES in a large Chinese pedigree [21],
and might disturb FOXL2 mRNA stability. Briefly, it would be
possible that a perturbation of FOXL2 expression through somatic
hypermethylation, locus heterozygous deletion or regulatory
mutations (i.e. in enhancer sequences, promoter, UTRs,…) could
play a role in malignant transformation, in a context where no
mutations in the coding region are detected. However, further
insights into the effects of the C134W mutation are required to
assess the plausibility of these hypotheses.
The Cys134 residue is conserved among a few forkhead
paralogs, including the only other member of the L subfamily,
FOXL1. Interestingly, FOXL1 has been shown to play a role in
carcinogenesis [22]. We therefore sequenced FOXL1 in the NCI-
60 cell line panel. We failed to detect any alteration of codon 129,
encoding the Cys paralogous to Cys134 in FOXL2. However, we
found several known or new polymorphisms in FOXL1, which are
reported in the Table S2.
Subcellular Localization and Mobility of the FOXL2-
C134W Protein
Most of the described FOXL2 BPES-associated mutations have
been found to induce either nuclear aggregation or cytoplasmic
delocalization and aggregation, and this has been suggested to
participate in the BPES pathogenesis at the molecular/cellular
level [23,24,25,26,27]. Interestingly, missense mutations in the
Forkhead domain of FOXL2 often lead to subcellular mislocaliza-
tion and protein aggregation [23]. Moreover, when investigated,
FOXL2 protein aggregation was associated with impaired FOXL2
protein mobility [25]. Therefore, we studied the subcellular
localization of a FOXL2-C134W-GFP fusion protein in COS-7
cells, which are readily transfectable and that we have often used
to study mutant FOXL2 localization. We observed no significant
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(data not shown). In this respect, the mutant protein behaves quite
similarly to the wild-type (WT) one. Our observations in
transfected cells are compatible with the immunohistochemistry
findings by Shah and collaborators in tumors carrying the
mutation, which suggested no effect on protein localization [12].
However, as at least one mutant FOXL2 protein presents an
impaired protein mobility without visible aggregation (namely, the
pathogenic expansion of the polyalanine domain to 19 residues;
[25]), we investigated whether the mobility of the FOXL2-C134W
was different from that of the WT protein, also including as a
control the FOXL2-Ala19 variant (Figure 1). The mutant protein
did not display any perturbation of its mobility as compared to the
WT (t1/2=7.0660.81 and t1/2=6.0561.08 respectively;
p=0.45), contrary to the FOXL2-Ala19 variant, which was found
unable to recover from photobleaching, as previously described
[25]. This suggests that FOXL2-C134W is fully diffusible in the
nucleus, and that it should be able to readily reach its target
promoters.
Transactivation Capacity of FOXL2-C134W on Known
Target Promoters
Since subcellular localization and solubility of FOXL2-C134W
were not significantly different from those of the WT protein, then
we studied its transactivation capacity on a panoply of luciferase
reporters known to respond to FOXL2, looking for potential
dysregulations. We either used reporters under the control of
naturally-occurring promoter sequences (pFoxL2-luc, IEX1-luc,
SIRT1-luc, pSODluc-3340 and OSR2-luc) or under the control of
artificial promoters responsive to FOXL2 (2xFLRE-luc, 4xFLRE-
luc, 4xmFLRE-luc and 3xGRAS-luc). Using these reporters to
assess the molecular phenotype of the FOXL2-C134W mutant is
relevant, because their promoters have been previously shown to
display various affinity levels and specific behaviors towards
distinct types of FOXL2 mutations [23,25,27,28]. As control
mutations, we also included a representative BPES type I-causing
variant (FOXL2-I80T), which is associated with granulosa cell
dysfunction, and a representative BPES type II-causing variant
(FOXL2-N109K), which is associated with normal ovarian
function, to compare the molecular behavior of the FOXL2-
C134W cancer-associated variant with BPES-causing mutations.
First, we performed the luciferase assays in the adult OGCT-
derived KGN cell line, even if it carries the p.Cys134Trp mutation
at the heterozygous state, because these cells have been shown to
be good models of granulosa cells [16] and because, we
hypothesized, overexpression of the FOXL2 variants should
outweight the endogenous protein levels in this kind of assay
(Figure 2).
In most cases, FOXL2-C134W behaved similarly to the WT
protein (Figure 2B–E, 3G–H), as is the case for the typical type II-
associated missense mutant FOXL2-N109K, whereas the type I-
associated mutant FOXL2-I80T always behaved like a null
mutation. In this respect, the behavior of type I and II-associated
variants is consistent with previous studies [27]. In other instances
(A, F), both FOXL2-C134W and FOXL2-N109K present an
activity slightly enhanced as compared to the wild-type protein.
These increases are not necessarily relevant from a physiological
viewpoint, as BPES type II-associated mutants, such as FOXL2-
N109K, do not impair granulosa cell function [1,2,27], and induce
no ovarian cancer predisposition, as in all cases of BPES reported
so far.
Surprisingly, in the particular case of 3xGRAS-luc, the FOXL2-
C134W variant seemed hyperactive as compared to the WT
protein (I), whereas both FOXL2-I80T and FOXL2-N109K were
hypomorphic. It is noteworthy that this is the first published
occurrence of a BPES type II-associated missense variant
displaying such low activity on a promoter reporter, which
strongly suggests that the 3xGRAS-luc reporter is a very low-
affinity target of FOXL2. Reporter 3xGRAS-luc (GRAS: GnRH
Receptor Activating Sequence) is a synthetic reporter, containing
three repeats of a composite regulating element (overlapping AP1,
Smad3 and Foxl2 binding sites) which is found in the murine
promoter of the GnRH Receptor (GnRHR) and seems to contribute to
the regulation of its expression in pituitary gonadotrope cells [29].
It has been shown that this sequence is bound by a Smad3-Foxl2
heterodimer [29]. Though it is best known and studied in the
pituitary, recent evidence suggests that the GnRH/GnRHR
system is present in the ovary [30,31]. However, the physiological
implications of this are still unclear. Our luciferase results therefore
seem to indicate that the p.Cys134Trp mutation could induce a
disruption of normal FOXL2/SMAD3 interaction.
To address the concern that half of endogenous FOXL2 in KGN
cells involves the very C134W variant, which is under study, we
decided to study the effects of the p.Cys134Trp mutation in the
cervical cancer HeLa cell line (Figure 3). According to the BioGPS
portal, HeLa cells (from the NCI-60 panel) express FOXL2 at
detectable levels (http://biogps.gnf.org/#goto=genereport&id=
668; U133A gcrma, chip 220102_at), so they should be able to
manage transfected FOXL2 and add the correct post-translational
modifications necessary for FOXL2 activity. Moreover, according
to FOXL2 EST expression profile from the Unigene database
(Hs.289292), FOXL2 is expressed at significant levels in both healthy
uterus and cervix, which makes HeLa cells, as a cervical cell line, a
fairly good model to study FOXL2 activity.
In the case of the pFoxL2-luc, SIRT1-luc, OSR2-luc,
2xFLRE-luc and 4xFLRE-luc reporters, the behavior of the
FOXL2-C134W mutant was much like what we had observed in
KGN cells (Figure 3A, C, E–G). Interestingly, on the target
stress-response reporters promoter (i.e. MnSOD=pSODluc3340
and IEX1/IER3=IEX1-luc), we found that the FOXL2-
C134W mutant was just slightly, but significantly, hypomorphic
in HeLa cells, whereas it had similar activity to the WT in KGN
cells (Figure 3B, D). In our opinion, this could indicate that
according to different proteomic contexts (i.e. HeLa versus
KGN), the FOXL2-C134W mutant may lead to slightly different
(impaired?) stress responses. We also found that FOXL2-C134W
was slightly hypermorphic on the 4xmFLRE-luc promoter in
HeLa cells, whereas it showed WT-like activity in KGN cells
(Figure 3H). However, the biological relevance of this finding is
to be determined since the 4xmFLRE-luc reporter is an artificial
one.
Finally, on the 3xGRAS-luc reporter, the FOXL2-C134W
mutant protein was hypomorphic as compared to the WT in HeLa
cells, which would indicate once again a potentially disrupted
FOXL2/SMAD3 interaction (Figure 3I). This result seems to
contradict what we obtained in KGN cells, where FOXL2-
C134W was hypermorphic on this articifial promoter. However,
as KGN and HeLa cells are derived from different tissues, we
cannot exclude cell-type-dependent differences of SMAD hetero-
dimerization with FOXL2. Moreover, as 3xGRAS-luc is an
artifical promoter, and that other transcription factor binding sites
surrounding the sites in naturally occurring promoters are lacking,
fine tissue-dependent regulations can be absent and might induce
such an apparently contradictory behavior.
It has recently been shown that mouse Foxl2 interacts with
Smad3 through the C-terminal part of its Forkhead domain [32].
The Forkhead domain sequence of human FOXL2 and mouse
Foxl2 are strictly conserved [4], and the Cys134 residue of the
The FOXL2 p.Cys134Trp Mutation
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FOXL2. The sequence encompassing amino acids 132 to 161 inthe
mouse Foxl2 protein sequence was found to be crucial for Foxl2/
Smad3 interaction [32]. The proximity between the interaction
motif of Foxl2 and Smad3 and the recurrent Cysteine residue
mutated in cancer, in conjunction with the atypical behavior of
FOXL2-C134W on the known Foxl2/Smad3 target 3xGRAS-luc
in both KGN and HeLa cells, may suggest that the specific
pathogenesis of this cancer-related mutation could result, at least in
part, from a modification of the Foxl2-Smad interaction in the
Figure 1. Analysis of FOXL2-C134W-GFP protein mobility by Fluorescence Recovery after Photobleaching in COS-7 cells nuclei. (A)
In each mutant case, the leftmost panel shows the GFP fusion proteins in the nuclei prior to photobleaching, the second panel (0 s) shows the GFP
fusion proteins immediately after bleaching (the white arrows indicate the bleached portion, which appear as black regions). The next two panels
show fluorescence recovery after 5 and 15 s respectively. FOXL2-Ala19-GFP is shown as a control FOXL2 mutant which has a rather homogeneous
nuclear distribution in transfected cells, but whose protein mobility is compromised, as described previously [25]. Notice that Fluorescence is
recovered for both the WT and C134W variants, but not the Ala19 variant. (B) Graphs reporting fluorescence in the bleached zone as a function of
time are reported. Data was computed for 21 cells and 22 cells for the WT and C134W FOXL2 variants respectively, and the average fluorescence
values are plotted. Fluorescence was recovered in both cases, and recovery times were not significantly different between the two different FOXL2-
GFP variants.
doi:10.1371/journal.pone.0008789.g001
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PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8789Figure 2. Luciferase assays show that the FOXL2-C134W variant seems fully functional in adult OGCT KGN cells. Luciferase assays in
KGN cells transfected with pFoxL2-luc (A), IEX1-luc (B), SIRT1-luc (C), pSODluc-3340 (D), OSR2-luc (E), 2xFLRE-luc (F), 4xFLRE-luc (G), 4xmFLRE-luc (H) or
3xGRAS-luc (I). In each case, the experiment is conducted in presence of either the empty control vector (pcDNA3.1-GFP), or the expression vectors
for the FOXL2-WT version, the representative BPES type I-inducing variant FOXL2-I80T, the representative BPES type II-inducing variant FOXL2-N109K
or the OCGT-associated FOXL2-C134W version. Statistical significances from an ANOVA, followed by post-hoc Tukey HSD tests, for values compared
to FOXL2-WT are reported. n.s.: non-significant; *: p,0.05; **: p,0.01.
doi:10.1371/journal.pone.0008789.g002
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PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8789Figure 3. Luciferase assays show that the FOXL2-C134W variant seems functional in cervical cancer HeLa cells. Luciferase assays in
HeLa cells transfected with pFoxL2-luc (A), IEX1-luc (B), SIRT1-luc (C), pSODluc-3340 (D), OSR2-luc (E), 2xFLRE-luc (F), 4xFLRE-luc (G), 4xmFLRE-luc (H)
or 3xGRAS-luc (I). In each case, the experiment is conducted in presence of either the empty control vector (pcDNA3.1-GFP), the expression vector for
the FOXL2-WT version, or the OCGT-associated FOXL2-C134W version. Statistical significances from an ANOVA, followed by post-hoc Tukey HSD tests,
for values compared to FOXL2-WT are reported. n.s.: non-significant; *: p,0.05; **: p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0008789.g003
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relevant in the case of a cancer-associated mutation, since Smad3
has been shown to be a key mediator of the TGF-b cytostatic
program [33]. All in all, these findings and hypotheses require
further studies in the context of naturally-occurring ovarian
FOXL2-responsive promoters containing FOX-SMAD binding
sites. Such promoters are, unfortunately, yet to be characterized.
We have recently shown that FOXL2 is involved in the cellular
response to oxidative stress [34]. Among other things, we have
shown that FOXL2 transactivation was increased in response to
cell stress, notably on the promoter of the mitochondrial
Manganese Superoxide Dismutase (MnSOD), where the increase
in transactivation was stress-dose dependent. This was suggested to
help ovarian granulosa cells deal with a stress event [34,35].
Furthermore, an altered response to oxidative stress can have
genotoxic consequences, which is particularly important in the
ovary, considering the massive reactive oxygen species production
during ovulation [36]. Therefore, we studied whether the FOXL2-
C134W mutant protein was able to properly respond to an
oxidative stress stimulus using a stress-response reporter driven by
the MnSOD promoter (pSODluc-3340, Figure 4).
Oxidative stress of KGN cells induced an increase of
transactivation of both the WT and the C134W mutant to a
similar extent, suggesting that the FOXL2-C134W variant is able
to respond appropriately to stress. Therefore, the potential defect
induced by the p.Cys134Trp mutation might not lie in an altered
response to cellular stress (which can contribute to the appearance
and development of cancer). However, further studies may be
necessary to completely rule out a potentially dysregulated stress
response in the pathogenesis of the p.Cys134Trp mutation.
3D-Modeling of the Consequences of FOXL2 Mutation
p.Cys134Trp
The forkhead domain of FOXL2 can be structurally accommo-
dated into the same tertiary and quaternary association which was
reported for the forkhead domain of FOXP2 [37]. We have
previously obtained a preliminary model in order to explore the
possible effects of FOXL2 disease-causing mutants according to
their predicted structural positioning [26]. We had then shown that
it was possible to sort the mutants into two classes: those that should
alter protein interactions within and between FOXL2 molecules
and those that should disrupt the interaction of FOXL2 with DNA
[26]. The 3D-models for WT-WT and C134W-C134W protein
homodimers bound to DNA are displayed in Figure 5.
Our model predicts that the cancer-associated p.Cys134Trp
mutation is likely to affect the protein/protein homotypic
interaction. Unfortunately, the protein region beyond the forkhead
is not present in our model, since there is no readily available
structural template, so potential interactions of Cys134 or its
mutated counterpart with regions outside of the Forkhead domain
cannot be modeled. However, the primary sequence of FOXL2 in
this region suggests a disordered chain, which could become
ordered upon interaction. Such a potential mechanism might be
affected by the mutation, leading to a global altered conformation
in the mutant homodimer.
Finally, it has previously been suggested that the DNA-binding
specificity of Forkhead factors is partially determined by highly
variable sequences in the wings W1 and W2 that could adopt
specific conformations and guide the precise positioning of the H3
recognition Helix during DNA binding [38]. Interestingly, these
sequences are highly conserved in the case of FOXL2, and the
somatic cancer-associated p.Cys134Trp mutation affects the
predicted second wing region W2 (Figure 5). This mutation might
therefore also disturb the specificity of recognition of a set of
promoters relevant to carcinogenesis, or even induce an ectopic
modulation of heterologous targets. A potential perturbation of the
interaction between mutant FOXL2 and other co-factors, such as
Smad3 also remains to be studied.
Concluding Remarks
Contrary to most BPES-causing mutations, the cancer-associ-
ated p.Cys134Trp mutation does not have a strong impact on
FOXL2 localization, mobility and transactivation abilities on
several reporter promoters. Our luciferase assays indicate that this
mutation is neither a dominant-negative nor a loss-of-function
mutation on the tested promoters. The case of 3xGRAS-luc
suggests that specific signaling pathways could be differentially
misregulated by this mutant and would promote malignant
transformation while generally maintaining a correct regulation
pattern of FOXL2 targets. Understanding the exact pathogenic
mechanism underlying the effects of the p.Cys134Trp mutation
will therefore require high-throughput unbiased studies, so as to
uncover the specifically disturbed FOXL2-regulated functions.
Working with over-expressed FOXL2 variants presents some
shortcomings, as some fine-tuned effects, as is often the case for
cancer-associated mutations, could be overlooked in this context.
However, this also means that studies performed using over-
expressed FOXL2 in cultured cells, which will thus be predom-
inant as compared to the endogenous protein, might still yield
results informative of the transfected variant, regardless of the cell
genotype (i.e. as illustrated by the coherent behavior of WT
FOXL2 and the BPES-inducing mutations in KGN cells). It is also
worth noting that, as more than 95% of adult OGCTs are carriers
of the c.402C.G mutation [12], the relevance of OGCT-derived
cell lines not carrying this particular alteration to study this type of
cancer is not clear.
Materials and Methods
Genomic DNA Extraction and Sequencing
NCI-60 panel genomic DNA were obtained from the National
Cancer Institute (after submission of a project involving a formal
Figure 4. FOXL2-C134W transactivation is increased upon
oxidative stress to the same extent as for the WT version.
Luciferase assays in KGN cells using the MnSOD promoter reporter
pSODluc-3340, with empty control vector, FOXL2-WT or FOXL2-C134W
overexpression vectors, to assess the effect of a 2h-treatment with
150 mMH 2O2 on the activity of the FOXL2 versions. The increase of
FOXL2 transactivation ability observed upon oxidative stress, which we
have previously reported for WT FOXL2 [34], is similar (i.e. not
statistically different) in the cases of the WT and of the cancer-
associated FOXL2-C134W variant.
doi:10.1371/journal.pone.0008789.g004
The FOXL2 p.Cys134Trp Mutation
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8789request) and genomic DNA from 34 CRC cell lines from Sir
Walter Bodmer’s laboratory [18]. Genomic DNA from cultured
KGN (obtained from the Nawata laboratory [16]) and JEG-3
cells (kindly provided by Dr. D. Vaiman, Institut Cochin, Paris)
was extracted using a classical Miller’s method. The full-length
FOXL2 (FOXL1) ORF was amplified using a touch-down PCR
approach, using the High-Fidelity Taq Polymerase (Invitrogen).
The amplicons were then analyzed using single-pass automated
bi-directional Sanger sequencing (BigDye v3.1, Applied Biosys-
tems) and capillary electrophoresis (ABI 3730xl, Applied
Biosystems). All primers are available upon request. Sequence
analysis was performed manually to detect potential variants.
Numbering of sequence variants was performed following the
HGVS Mutation Nomenclature Recommendations (http://
www.hgvs.org/mutnomen/recs.html), using reference sequence
AF301906.1.
Plasmids
The luciferase reporter plasmids used in this study were
described previously: IEX1-luc [39], pFoxL2-luc [40], SIRT1-
luc [34], pSODluc-3340 [41], 2xFLRE-luc, 4xFLRE-luc and
4xmFLRE-luc [42], 3xGRAS-luc [29] and OSR2-luc [43].
FOXL2-GFP variants expression vectors are based on a
pcDNA3.1 backbone and have been described previously:
FOXL2-WT [25], FOXL2-Ala19 [25], FOXL2-I80T [23]
and FOXL2-N109K [23]. The FOXL2-C134W expression
vector was obtained using junction-PCR as previously described
[25].
Cell Culture, Transfections and Luciferase Assays
COS-7 and HeLa cells, obtained from ATCC, were cultured in
DMEM medium, supplemented with 10% FBS and 1%
penicillin/streptomycin (Invitrogen-Gibco). KGN cells [16] were
grown in DMEM-F12 medium, supplemented with 10% FBS and
1% penicillin/streptomycin (Invitrogen-Gibco). KGN (respectively
HeLa) cells were plated 12 h prior to transfection at a density of
4610
4 cells.cm
22 (2.5610
4 cells.cm
22) and transfected using the
calcium-phosphate method [44]. For luciferase assays, KGN and
HeLa cells were seeded in 24-well plates. A Renilla luciferase
reporter driven by the RSV promoter (Promega) was included as
an internal control of transfection efficiency. Luciferase activity
quantification was performed as previously described [25].
Relative luciferase units are the ratio of Firefly over Renilla
luciferase activity, and come from at least 5 biologically
independent replicates. Statistical significance was estimated by
one-way ANOVA or Student t-tests as relevant.
Exposure of Cultured Cells to Oxidative Stress
To induce oxidative stress, H2O2 was added to KGN cell
culture media to 150 mM for 2 h prior to cell lysis as previously
described [34].
Fluorescence Recovery after Photobleaching (FRAP)
Experiments
FRAP experiments were conducted as previously reported [25].
Briefly, COS-7 cells were transfected with either FOXL2-WT-
Figure 5. 3D structural model of WT and C134W FOXL2 proteins. (A) FOXL2 Forkhead domain protein sequence. Secondary structures are
indicated at the top, with barrels for a-helices (H1 to H4) and open arrows for b-strands (S1 to S3). Black symbols indicate structures typical of all
Forkhead domains, while H4 is indicated in gray, as it was predicted to exist in the case of FOXL2 by sequence homology, though no crystal data is
directly available. Cys134 is highlighted in red in the predicted second Wing structure. (B–C) Structural models of the FOXL2 forkhead domains in a
dimer conformation, fitted to the experimental structure of the FOXP2/DNA crystal [37]. WT (B) and C134W (C) dimers are represented. The proteins
are displayed as red and pinks ribbons and DNA is shown in blue as a stick model. The residue at the 134
th position is shown as a molecular model in
3D.
doi:10.1371/journal.pone.0008789.g005
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plates, perforated, and containing a sterile glass coverslip on the
bottom. 48 h after transfection, we performed photobleaching
experiments and fluorescent image acquisitions using a LEICA
TCS SP2 AOBS confocal microscope. The 30 mW Argon/Neon
laser was used at 100% power for photobleaching (2 times, with a
lag between bleaching events of 1.635 s). Data were collected from
21 or 22 different cells for each condition. Image analysis was
performed with the ImageJ software. Results are mentioned in the
text plus or minus SEM.
In Silico 3D-Modeling of WT and C134W FOXL2
Homodimers
The forkhead domain of FOXL2 was modeled using the crystal
structure of the forkhead domain of FoxP2 as template (PDB
accession number: 2A07) [26,37]. The homology module from the
Insight 2000 Accelrys software on SGI-O2 was used for the 3D-
modeling. The p.Cys134Trp mutant was incorporated in the
forkhead domain of FOXL2 using standard rotamer geometry in
the biopolymer module of the Accelrys software. The stoechio-
metry of six Forkhead domains for two DNA molecules which was
observed in the experimental FoxP2 forkhead domain crystal
structure [37] was used to model the association of the native and
mutated FOXL2 forkhead domain to DNA, in order to
understand the possible effects of the mutant.
Supporting Information
Figure S1 Sequencing chromatograms for FOXL2 in the panels
of sequenced cell lines. Portions of the sequencing chromatograms
of choriocarcinoma JEG-3 cell line (A) and of the adult ovarian
granulosa cell tumor KGN cell line (B) around nucleotide 402 of
the coding region. We also report the presence of a new noncoding
polymorphism (C) and of already described noncoding SNPs,
found in cis (D).
Found at: doi:10.1371/journal.pone.0008789.s001 (1.22 MB
DOC)
Table S1 Analysis of FOXL2 genotype in various established cell
lines at position c.402.
Found at: doi:10.1371/journal.pone.0008789.s002 (0.13 MB
DOC)
Table S2 Analysis of FOXL1 genotype in various established cell
lines.
Found at: doi:10.1371/journal.pone.0008789.s003 (0.15 MB
DOC)
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